Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution
Autore:
Sanz, GF; Saavedra, S; Jimenez, C; Senent, L; Cervera, J; Planelles, D; Bolufer, P; Larrea, L; Martin, G; Martinez, J; Jarque, I; Moscardo, F; Plume, G; Andreu, R; de la Rubia, J; Barragan, E; Solves, P; Soler, MA; Sanz, MA;
Indirizzi:
Univ Valencia, Hosp La Fe, Hematol Serv, Dept Hematol,Bone Marrow Transplantat Unit, Valencia 46009, Spain Univ Valencia Valencia Spain 46009 nsplantat Unit, Valencia 46009, Spain Univ Valencia, Hosp La Fe, Dept Clin Pathol, Mol Biol Lab, Valencia 46009,Spain Univ Valencia Valencia Spain 46009 l, Mol Biol Lab, Valencia 46009,Spain Ctr Trasfus Comunidad Valenciana, Valencia, Spain Ctr Trasfus Comunidad Valenciana Valencia Spain nciana, Valencia, Spain
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 7, volume: 27, anno: 2001,
pagine: 693 - 701
SICI:
0268-3369(200104)27:7<693:UDCBTI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC MYELOID-LEUKEMIA; POLYMERASE-CHAIN-REACTION; VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; PLACENTAL-BLOOD; ENGRAFTMENT; RECONSTITUTION; RECIPIENTS; INTERFERON;
Keywords:
cord blood transplantation; unrelated donor; hematopoietic stem cell transplantation; chronic myelogenous leukemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Sanz, MA Univ Valencia, Hosp La Fe, Hematol Serv, Dept Hematol,Bone MarrowTransplantat Unit, Av Campanar 21, Valencia 46009, Spain Univ Valencia Av Campanar 21 Valencia Spain 46009 a 46009, Spain
Citazione:
G.F. Sanz et al., "Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution", BONE MAR TR, 27(7), 2001, pp. 693-701

Abstract

The potential role of unrelated donor cord blood transplantation (UD-CBT) in adults is not well established. We report the results of UD-CBT in nine adult patients with chronic myeloid leukemia (CML). The median age was 27 years (range, 19-41 years), and the median weight was 62 kg (range, 45-78 kg), At transplant, six patients were in chronic phase (five in first, and one in second), two in blast crisis, and one in accelerated phase. Eight had received intensive chemotherapy, and three had undergone autologous peripheral blood hematopoietic stem cell transplantation. Four had received interferon with no cytogenetic response, and only three underwent UD-CBT within 1gear of diagnosis. After serological typing for class I antigens, and high-resolution DNA typing for DRB1, the degree of HLA match between patients and cord blood (CB) units was 4/6 in six cases and 5/6 in three cases. The median number of nucleated cells infused was 1.7 x 10(7)/kg (range, 1.2 to 4.9x10(7)/kg), and was above 2x10(7)/kg in only two cases. All patients received thiotepa, busulfan, cyclophosphamide and anti-thymocyte globulin as conditioning; cyclosporine and prednisone for graft-versus-host disease (GVHD) prophylaxis; and G-CSF from day +7 until engraftment, All seven evaluablecases engrafted, The median time to reach an absolute neutrophil count greater than or equal to0.5x10(9)/l and greater than or equal to 1x10(9)/l was22 days (range, 19-52 days) and 28 days (range, 23-64 days), respectively. In the four patients evaluable for platelet recovery time to levels of greater than or equal to 20x10(9) platelets/l, greater than or equal to 50x10(9) platelets/l, and greater than or equal to 100x10(9) platelets/l, these ranged from 50 to 128 days, 60 to 139 days, and 105 to 167 days, respectively. Three patients developed acute GVHD above grade II, and three of the five patients at risk developed extensive chronic GVHD. Four patients, all transplanted in chronic phase, remain alive in molecular remission more than 18, 19, 24 and 42 months after transplantation. These preliminary results suggest that UD-CBT may be considered a reasonable alternative in adults withCML who lack an appropriate bone marrow donor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 22:40:20